Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
18 juin 2024 07h00 HE
|
Chemomab Therapeutics
New publication confirms the role of CCL24 in primary sclerosing cholangitis and the potential of CM-101 to impact PSC disease progression and severity.
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
06 juin 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab presents new data supporting clinical potential of CM-101 as novel treatment for PSC at EASL 2024 and Gordon Research Conference
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
17 mai 2024 07h00 HE
|
Chemomab Therapeutics
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for...
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab reported on major progress in Q1 2024, including that it is on track to report Phase 2 PSC topline data at midyear 2024
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
08 mai 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab has been granted another 180-day extension to regain compliance with the minimum bid price requirement in order to remain listed on Nasdaq.
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
02 mai 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab CEO Adi Mor will present at the Aegis Virtual Conference on May 7 at 9:00am ET
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
24 avr. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab will release its first quarter 2024 financial results and provide a corporate update on May 9, 2024.
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
18 avr. 2024 07h00 HE
|
Chemomab Therapeutics
Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
02 avr. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 mars 2024 07h06 HE
|
Chemomab Therapeutics
Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories.